Headlands Research has announced the acquisition of Trial Management Associates (TMA). The addition of TMA extends Headlands Research’s southeastern U.S. geographical reach. The Headlands Research network now includes 21 sites across the United States and Canada. Financial terms of the deal were not disclosed.
TMA is a multi-site clinical research company with locations in North and South Carolina. The company is headquartered in Wilmington, North Carolina, with an additional location in Myrtle Beach, South Carolina. TMA brings experience across various therapeutic specialties, including vaccines, endocrinology and more.
Headlands Research, a portfolio company of KKR & Co., is a globally integrated clinical trial site organization. Headlands Research has successfully completed more than 5,000 clinical trials.
“The acquisition of TMA further demonstrates our commitment to strategic growth,” said Kyle Burtnett, CEO of Headlands Research. “By adding TMA to our ever-expanding network of clinical trial sites, we are providing sponsors with more geographic options, larger and more diverse participant pools, and a greater depth of knowledge in two of our core clinical areas.”
According to data captured in the LevinPro HC database, this acquisition represents the 26th clinical trial deal of 2024. There were 42 clinical trial transactions announced during 2023, and 30 announced during 2022. Headlands Research had three deal announcements during 2023, and one during 2022. Since June 2022, the company has acquired Peninsula Research Associates, Headlands Research Eastern Massachusetts, Clinvest Research, AMCR Institute and Clinical Research Professionals.
